GUANGZHOU, CHINA--(Marketwired - February 22, 2016) - Science to Consumers Inc. (OTCQB: BEUT) (The Company) is pleased to announce that on December 29, 2015 the Company signed a five-year exclusive licensing agreement with Biomatrix, Inc. for the People’s Republic of China and Europe.
Science to Consumers, Inc., is focused on anti-aging and good-for-your-body products. Utilizing 21st century science and cost-effective high-return marketing, the Company is poised to take advantage of the aging of the largest single demographic group in history, the baby boomers.
The agreement will allow Science to Consumers Inc., to market and sell at least six of its special formulated anti-aging products including the DermaLastyl line. The first products the Company plans to sell are DermaLastyl skin care products. DermaLastyl is a trademarked anti-aging cream that helps to reduce wrinkles through the use of revolutionary science. The key ingredient, Tropoelastin, is a patented formulation of elastin produced by genetic engineering that promotes healing and renewing of the skin.
Protein Genomics, Inc., based in Flagstaff, Arizona, created Tropoelastin specifically to heal wounds. The Company, now through its agreement with Biomatrix, Inc., has the exclusive license and rights to market Tropoelastin for cosmetic applications in the markets of China and Europe.
The patented science and IP technology licensed to the Company provides an advantage over the competition because DermaLastyl actually repairs and heals damaged elastin, thus reversing the appearance of aging.
The DermaLastyl line are genetically engineered products on the market that helps restore elastin and elastic properties to the skin and around the eyes.
“Science to Consumers and Biomatrix Inc. have worked diligently over the past year to finalize this agreement and we are ecstatic to implement these ground-breaking products to the Chinese and European markets. Anti-aging products represent a multi-billion-dollar industry and I am confident with our marketing and e-commerce expertise we will have unlimited opportunities to service this growing market,” stated Edwon Lam, the Chief Executive Officer for Science to Consumers Inc.
“We look forward to working very closely with Mr. Burt Ensley and Biomatrix Inc., in preparation for our market and product launch of these special formulated products,” concludes Edwon Lam, CEO of the Company.
The complete licensing agreement including the terms and conditions and additional Company filings can be found at www.sec.gov
For more information about the Company please visit our website at www.sciencetoconsumers.com
About Science to Consumers Inc. (the “Company”)
Science To Consumers Inc., is a marketing and sales Company that has licensed its products from a biotechnology company that designs and manufactures sophisticated, high performance biomaterials such as Elastatropin for use in the cosmeceutical and personal care markets. Science to Consumers, Inc., is focused on anti-aging and good-for-your-body products. Utilizing 21st century science and cost-effective high-return marketing, the Company is poised to take advantage of the aging of the largest single demographic group in history -- baby boomers.
The core product the Company plans to sell is DermaLastyl skin care products. DermaLastyl is a trademarked anti-aging cream that helps to reduce wrinkles through the use of revolutionary science. The key ingredient, to the DermaLastyl products is Tropoelastin, which is a patented formulation of elastin produced by genetic engineering that promotes healing and renewing of the skin. Through its agreement with Biomatrix, Inc., the Company has the exclusive license and rights to market Tropoelastin for cosmetic applications in China and Europe.
Forward Looking Statements
Some information in this document constitutes forward-looking statements or statements which may be deemed or construed to be forward-looking statements, such as the signing of the exclusive license. The words “plan”, “forecast”, “anticipates”, “estimate”, “project”, “intend”, “expect”, “should”, “believe”, and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause the Company’s actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in the Company’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Science To Consumers Inc., herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Science To Consumers Inc., disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.
For further information, please contact:
Science To Consumers Inc.
Email: investor@sciencetoconsumers.com
